Bacteria: Driving polar growth
Bacteria come in a variety of shapes and sizes – some are round, some are spiral and some are rod-shaped. The mechanisms that bacteria use to generate and maintain these diverse shapes as they grow is an area of active research (Kysela et al., 2016). The cell wall of bacteria contains a net-like structure called peptidoglycan, and it is thought that this structure maintains the shape of the cell (Egan et al., 2017). As bacteria grow, nascent peptidoglycans and other materials are inserted into the cell wall in a complicated process involving multiprotein complexes that contain various enzymes (Höltje, 1998; Pazos et al., 2017).
The process of cell wall growth has been widely studied in rod-shaped bacteria such as Escherichia coli and Bacillus subtilis, which grow by adding new material to the long sidewalls of the cell rather than to the ends (Daniel and Errington, 2003). But not all rod-shaped bacteria grow this way. For example, bacteria belonging to the Actinobacteria phylum – which includes the pathogens that cause tuberculosis, leprosy, and diphtheria – grow by adding new material to the ends (or poles) of the cell (Kieser and Rubin, 2014; Cameron et al., 2015).
It has been suggested that scaffold proteins and intermediate filaments target the machinery that synthesizes peptidoglycans to the cell poles, in order to restrict growth to this region (Letek et al., 2008; Fiuza et al., 2010). However, many aspects of polar growth, including the composition of the enzyme complexes and the cofactors involved, are still unknown. Now, in eLife, Joel Sher, Hoong Chuin Lim and Thomas Bernhardt from Harvard Medical School report how a newly discovered cofactor localizes a peptidoglycan synthase enzyme to the poles of bacterial cells (Sher et al., 2020).
To identify the components involved in polar growth, Sher et al. studied a library of 200,000 mutants of Corynebacterium glutamicum (a member of the Actinobacteria phylum) in which each strain is mutated for a specific gene or pathway. The bacteria were exposed to various stressful conditions or antibiotics, and a phenotypic profile was generated for each mutant based on how they responded. Further analysis revealed that genes which have a similar role, or work together in the same pathway, exhibit similar characteristics when mutated. This allowed Sher et al. to identify which genes are involved in polar growth.
Sher et al. studied the behavior of a previously unknown gene that codes for a protein named CofA. The phenotypic profile of CofA mutants was highly correlated with the profiles of strains carrying a genetic mutation in an enzyme called PBP1a, which synthesizes peptidoglycans. Fluorescent tagging revealed that CofA was localized at the cell poles of Corynebacterium, which is consistent with previous studies that found peptidoglycan synthases (such as PBP1a) to also be located at this region (Valbuena et al., 2007).
Individually deleting the genes that code for CofA and PBP1a showed that these two proteins depend on each other for their localization. Further experiments revealed that CofA acts as a cofactor and binds to the transmembrane domain of PBP1a, helping the enzyme accumulate at the tips of the cell.
Paralogs of the gene coding for CofA and its transmembrane domains are found throughout the Actinobacteria phylum. Sher et al. showed that CofA proteins in pathogenic bacteria, such as C. jeikium and M. tuberculosis, also interacted with their PBP1a counterpart in a specific manner. The CofA protein in M. tuberculosis was found to have an extended N-terminal cytoplasmic domain and deleting this region facilitated the interaction between CofA and PBP1a. However, the role of this N-terminal domain was not investigated further.
This study is the first to identify a conserved cofactor that modulates the behavior of peptidoglycan synthases in Actinobacteria. It also raises several tantalizing questions: Would removing CofA cause the growth of Corynebacterium to be less polar? Does deleting CofA and PBP1a change how peptidoglycan units are inserted into the cell wall? It would also be useful to mine the phenotypic profiles of other mutants to see if there are other unidentified cofactors of the PBP proteins.
Several disease-causing pathogens use this mode of polar growth, which is why it is important to study the components and mechanisms involved. The bacterial cell wall is repeatedly used as a target for antibiotic development. These findings could identify new drug targets, which may help combat the rising rates of antibiotic resistance, especially in the case of tuberculosis. Furthermore, the phenotype profiling approach used by Sher et al. could be used to determine the role of previously uncharacterized proteins and identify which proteins and genes participate in the same biological pathway.
References
-
The essential features and modes of bacterial polar growthTrends in Microbiology 23:347–353.https://doi.org/10.1016/j.tim.2015.01.003
-
Regulation of bacterial cell wall growthThe FEBS Journal 284:851–867.https://doi.org/10.1111/febs.13959
-
Phosphorylation of a novel cytoskeletal protein (RsmP) regulates rod-shaped morphology in Corynebacterium glutamicumJournal of Biological Chemistry 285:29387–29397.https://doi.org/10.1074/jbc.M110.154427
-
Growth of the stress-bearing and shape-maintaining murein sacculus of Escherichia coliMicrobiology and Molecular Biology Reviews 62:181–203.https://doi.org/10.1128/MMBR.62.1.181-203.1998
-
How sisters grow apart: mycobacterial growth and divisionNature Reviews Microbiology 12:550–562.https://doi.org/10.1038/nrmicro3299
-
DivIVA is required for polar growth in the MreB-lacking rod-shaped actinomycete Corynebacterium glutamicumJournal of Bacteriology 190:3283–3292.https://doi.org/10.1128/JB.01934-07
-
Robust peptidoglycan growth by dynamic and variable multi-protein complexesCurrent Opinion in Microbiology 36:55–61.https://doi.org/10.1016/j.mib.2017.01.006
Article and author information
Author details
Publication history
Copyright
© 2020, Dhar
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,124
- views
-
- 77
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Microbiology and Infectious Disease
As the largest mucosal surface, the gut has built a physical, chemical, microbial, and immune barrier to protect the body against pathogen invasion. The disturbance of gut microbiota aggravates pathogenic bacteria invasion and gut barrier injury. Fecal microbiota transplantation (FMT) is a promising treatment for microbiome-related disorders, where beneficial strain engraftment is a significant factor influencing FMT outcomes. The aim of this research was to explore the effect of FMT on antibiotic-induced microbiome-disordered (AIMD) models infected with enterotoxigenic Escherichia coli (ETEC). We used piglet, mouse, and intestinal organoid models to explore the protective effects and mechanisms of FMT on ETEC infection. The results showed that FMT regulated gut microbiota and enhanced the protection of AIMD piglets against ETEC K88 challenge, as demonstrated by reduced intestinal pathogen colonization and alleviated gut barrier injury. Akkermansia muciniphila (A. muciniphila) and Bacteroides fragilis (B. fragilis) were identified as two strains that may play key roles in FMT. We further investigated the alleviatory effects of these two strains on ETEC infection in the AIMD mice model, which revealed that A. muciniphila and B. fragilis relieved ETEC-induced intestinal inflammation by maintaining the proportion of Treg/Th17 cells and epithelial damage by moderately activating the Wnt/β-catenin signaling pathway, while the effect of A. muciniphila was better than B. fragilis. We, therefore, identified whether A. muciniphila protected against ETEC infection using basal-out and apical-out intestinal organoid models. A. muciniphila did protect the intestinal stem cells and stimulate the proliferation and differentiation of intestinal epithelium, and the protective effects of A. muciniphila were reversed by Wnt inhibitor. FMT alleviated ETEC-induced gut barrier injury and intestinal inflammation in the AIMD model. A. muciniphila was identified as a key strain in FMT to promote the proliferation and differentiation of intestinal stem cells by mediating the Wnt/β-catenin signaling pathway.
-
- Microbiology and Infectious Disease
The drivers of tissue necrosis in Mycobacterium ulcerans infection (Buruli ulcer disease) have historically been ascribed solely to the directly cytotoxic action of the diffusible exotoxin, mycolactone. However, its role in the clinically evident vascular component of disease aetiology remains poorly explained. We have now dissected mycolactone’s effects on human primary vascular endothelial cells in vitro. We show that mycolactone-induced changes in endothelial morphology, adhesion, migration, and permeability are dependent on its action at the Sec61 translocon. Unbiased quantitative proteomics identified a profound effect on proteoglycans, driven by rapid loss of type II transmembrane proteins of the Golgi, including enzymes required for glycosaminoglycan (GAG) synthesis, combined with a reduction in the core proteins themselves. Loss of the glycocalyx is likely to be of particular mechanistic importance, since knockdown of galactosyltransferase II (beta-1,3-galactotransferase 6; B3GALT6), the GAG linker-building enzyme, phenocopied the permeability and phenotypic changes induced by mycolactone. Additionally, mycolactone depleted many secreted basement membrane components and microvascular basement membranes were disrupted in vivo during M. ulcerans infection in the mouse model. Remarkably, exogenous addition of laminin-511 reduced endothelial cell rounding, restored cell attachment and reversed the defective migration caused by mycolactone. Hence supplementing mycolactone-depleted extracellular matrix may be a future therapeutic avenue, to improve wound healing rates.